SCHEMBL5364353

SCHEMBL5364353

Nc1nc(CCc2ccccc2)nc2[nH]c(Br)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 6/20 0.43
ADORA2A P29274 3/20 0.43
ADORA2B P29275 2/20 0.43
DHFR P00374 1/20 0.40
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MMP12 P39900 1/20 0.38
NPC1 O15118 1/20 0.38
BACE1 P56817 1/20 0.38
ADORA3 P0DMS8 2/20 0.37
MPO P05164 1/20 0.36
PIM1 P11309 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363124 0.87 ADORA1 (0.46) ADORA1ADORA2AADORA2BADORA3PIM1
SCHEMBL5357833 0.83 ADORA1 (0.42) ADORA1ADORA2AADORA2BDHFRRAB9A
SCHEMBL5358009 0.81 ADORA1 (0.43) ADORA1ADORA2AADORA2BDHFRRAB9A
SCHEMBL5364358 0.77 ADORA2A (0.43) ADORA1ADORA2AADORA2BRAB9AALDH1A1
SCHEMBL5359002 0.76 MMP2 (0.45) ADORA1ADORA2AADORA2BSMN1; SMN2
SCHEMBL6346439 0.72 FBP1 (0.46) ADORA1ADORA2AADORA2BSMN1; SMN2PIM1
SCHEMBL5358350 0.72 FBP1 (0.46) ADORA1ADORA2AADORA2BDHFRBACE1
SCHEMBL5362133 0.71 FBP1 (0.46) ADORA1ADORA2AADORA2BRAB9AALDH1A1
SCHEMBL5369183 0.71 ADORA1 (0.38) ADORA1ADORA2AADORA2BADORA3
SCHEMBL5361170 0.69 HRH4 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285543-B2 Purine inhibitors of fructose-1,6-bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2007-10-23 US disclosed
US-20050277619-A1 Novel purine inhibitors of fructose-1,6-bisphosphatase DANG QUN 2005-12-15 US disclosed
US-6967193-B1 Purine inhibitors of fructose-1,6-bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2005-11-22 US disclosed
US-6284748-B1 ANTIDIABETIC AGENT METABASIS THERAPEUTICS, INC. 2001-09-04 US disclosed
WO-1998039344-A9 NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE 1999-01-21 WO disclosed
WO-1998039344-A1 NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE METABASIS THERAPEUTICS, INC. (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277619-A1 Novel purine inhibitors of fructose-1,6-bisphosphatase FBP1, PNP, PPA1 ADORA1 127/4885ADORA2A 319/4885ADORA2B 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.